- Home
- EQS vs KZIA Comparison
EQS vs KZIA Comparison
Compare EQS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- KZIA
- Stock Information
- Founded
- EQS 1991
- KZIA 1994
- Country
- EQS United States
- KZIA Australia
- Employees
- EQS N/A
- KZIA N/A
- Industry
- EQS Finance Companies
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- KZIA Health Care
- Exchange
- EQS Nasdaq
- KZIA Nasdaq
- Market Cap
- EQS 18.5M
- KZIA 18.7M
- IPO Year
- EQS N/A
- KZIA 1999
- Fundamental
- Price
- EQS $1.18
- KZIA $5.79
- Analyst Decision
- EQS
- KZIA Strong Buy
- Analyst Count
- EQS 0
- KZIA 1
- Target Price
- EQS N/A
- KZIA $20.00
- AVG Volume (30 Days)
- EQS 3.4K
- KZIA 123.2K
- Earning Date
- EQS 01-01-0001
- KZIA 11-29-2024
- Dividend Yield
- EQS N/A
- KZIA N/A
- EPS Growth
- EQS N/A
- KZIA N/A
- EPS
- EQS N/A
- KZIA N/A
- Revenue
- EQS $1,137,000.00
- KZIA $1,663,331.00
- Revenue This Year
- EQS N/A
- KZIA $802.53
- Revenue Next Year
- EQS N/A
- KZIA N/A
- P/E Ratio
- EQS N/A
- KZIA N/A
- Revenue Growth
- EQS 1795.00
- KZIA 10739.13
- 52 Week Low
- EQS $1.17
- KZIA $1.90
- 52 Week High
- EQS $1.95
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- EQS 37.54
- KZIA 52.56
- Support Level
- EQS $1.17
- KZIA $5.37
- Resistance Level
- EQS $1.25
- KZIA $6.01
- Average True Range (ATR)
- EQS 0.05
- KZIA 0.73
- MACD
- EQS -0.01
- KZIA -0.10
- Stochastic Oscillator
- EQS 4.00
- KZIA 45.55
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.